Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-02-09

Clinical Trial Update: A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ABP 501 with Humira in moderate to severe plaque psoriasis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ABP 501 (adalimumab biosimilar)
  • Humira (adalimumab)

Snippet

Sponsor: Amgen | Conditions: Plaque Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2024-02-09